Priority areas for future research include: (1) mechanistic validation of identified relationships, particularly the TFAP2E-microbiota axis; (2) characterization of AP-2 antisense transcripts, which are mentioned prominently but lack precise functional studies; (3) investigation of indirect mechanisms, such as microRNA-mediated regulation; (4) expansion to additional tumors or cancer subtypes, particularly those with established microbiome involvement; and (5) development of microbiome-based biomarker signatures incorporating AP-2 members for clinical implementation. This evidence concerns the gene TFAP2E and cancer.